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ABSTRACT
Individuals with hereditary diffuse gastric cancer (HDGC) caused by a CDH1
mutation have a high lifetime risk of developing gastric cancer. National guidelines
recommend CDH1 carriers undergo a prophylactic total gastrectomy (PTG)— a surgery
that greatly reduces the risk of developing gastric cancer but has significant comorbidities. This study explores the impact of a diagnosis of HDGC in the transitional
life stage between the ages of 18-29 deemed “emerging adulthood.” We surveyed 21
CDH1 carriers and conducted semi-structured phone interviews with 6 CDH1 carriers
between the ages of 18-29 to learn about their life experiences regarding education,
career, relationships, and family planning. Participants were also asked about their
experience with genetic counseling. Specific challenges that were highlighted by
participants included time away from work due to doctors’ appointments and surgery
recovery, an impact on relationships with family and friends, and difficult choices
regarding family planning. Participants also struggle with the burden of being the expert
on their condition in relation to their friends and healthcare providers, though they find
support and knowledge in online groups for HDGC. These results demonstrate the
challenges of an HDGC diagnosis during emerging adulthood. Practice recommendations
for genetic counselors include providing HDGC-specific information for anticipatory
guidance, family planning options, and psychological health.
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CHAPTER 1
LITERATURE REVIEW
1.1 Hereditary Diffuse Gastric Cancer
Gastric cancer is the fifth most prevalent and the third leading cause of cancerrelated death worldwide (Ferlay et al., 2012). While most gastric cancer is sporadic,
familial clustering is observed in 10% of cases, with 1-3% arising from known germline
mutations (van der Post et al., 2015). Hereditary diffuse gastric cancer (HDGC) is an
autosomal dominant cancer predisposition syndrome characterized by the development of
early-onset diffuse gastric cancer. HDGC is caused by germline, pathogenic mutations in
the tumor suppressor gene CDH1, located on chromosome 16. CDH1 encodes E-cadherin,
an intercellular adhesion glycoprotein that plays an essential role in epithelial
differentiation. A founder mutation in CDH1 was first identified in the Maöri population
of New Zealand in 1998 (Guilford et al., 1998). Since then, approximately 155
pathogenic germline mutations have been reported (van der Post et al., 2015). Most
pathogenic mutations in CDH1 lead to a non-functional protein product, resulting in loss
of cellular growth control and increased invasiveness into surrounding tissues (Fitzgerald
et al., 2010). HDGC is the only known cancer syndrome that is dominated by gastric
adenocarcinoma, though gastric cancer is indicated in other hereditary cancer syndromes
such as Li Fraumeni and Peutz-Jeghers (Guilford, Humar, & Blair, 2010; van der Post et
al., 2015). The lifetime risk of gastric cancer in these syndromes is variable but
consistently lower than that of HDGC (van der Post et al., 2015).
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The majority of gastric adenocarcinomas can be classified into one of two
categories: intestinal-type or diffuse-type. Intestinal-type adenocarcinomas are more
common in older patients and are associated with environmental factors such as H. pylori
infection. Globally, intestinal-type gastric cancers are on the decline, while diffuse-type
are on the rise (Pernot et al., 2015). Currently, diffuse-type adenocarcinomas, as seen in
HDGC, account for 35% of all stomach cancer diagnoses and are typically earlier-onset.
These cells are poorly differentiated and infiltrate nearby structures, spreading under
histologically normal-looking mucosa and causing linitis plastica, or thickening of the
wall. This type of cancer does not form a distinct mass, unlike intestinal-type gastric
cancer (Schneider, 2012). The accumulation of intracellular mucin pushes the nucleus
aside in these cells, causing a “signet ring” appearance. As such, this type of diffuse
gastric cancer is often referred to as signet ring cell carcinoma (SRCC). SRCC is a more
aggressive type of cancer and is associated with poorer outcomes (Volegaar et al., 2017).
1.2 Surveillance Guidelines and Recommendations
HDGC is highly penetrant, with a 70% risk of diffuse gastric cancer for men and a
56% risk for women by age 80. Women carry an additional 42% cumulative risk for
lobular breast cancer, compared to the typical lifetime risk of 12% (Hansford, Kaurah, &
Li-Chang, 2015). While surveillance by upper endoscopy is an option for CDH1 mutation
carriers, the earliest signs of diffuse gastric cancer are subtle changes of the stomach wall,
which are commonly missed (Schneider, 2012). Hebbard et al. (2009) retrospectively
analyzed pre- and post-PTG biopsies in 23 patients. While diffuse SRCC were found in
only 2 patients by upper endoscopy prior to surgery, final pathological evaluation postsurgery revealed SRCC in all but one patient (96%). Lynch et al. (2008) found that 10 of
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11 patients in their cohort who underwent PTG had occult carcinomas upon examination
of post-TG specimen. Six of these patients had undergone chromoendoscopy, endoscopic
ultrasound, random biopsies, and PET-CT scanning prior to surgery.
The identification of multiple small foci of SRCC in almost all CDH1 carriers,
including those in their teenage years, complicates the practicality of endoscopy for
patients. The average age of diagnosis of diffuse gastric cancer in HDGC patients is 38,
suggesting a prolonged latent phase before invasion of the submucosa. However, the
duration of this latent phase remains unpredictable and varies widely even within families
(Blair et al., 2006). As such, CDH1 carriers are advised to undergo a prophylactic total
gastrectomy (PTG) in their early twenties (van der Post et al., 2015).
1.3 Genetic Testing
According to National Comprehensive Cancer Network guidelines, one of the
following criteria qualifies an individual for a clinical diagnosis of HDGC, in addition to
genetic testing for pathogenic mutations in the CDH1 gene:
1) Two gastric cancer cases in a family, with one confirmed diffuse gastric cancer
diagnosed under 50 years;
2) Three confirmed cases of diffuse gastric cancer in first- or second-degree
relatives independent of age;
3) Diffuse gastric cancer diagnosed before age 40 without a family history;
4) A personal or family history of diffuse gastric cancer and lobular breast cancer,
with one diagnosis under 50 (NCCN, 2018).
While a confirmed pathogenic mutation in the CDH1 gene is effectively a diagnosis of
HDGC, not having a mutation does not rule out a diagnosis based on personal and family
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history. In fact, the majority of individuals with a diagnosis of HDGC do not have an
identifiable genetic cause, as only 40% of families meeting testing criteria have a
germline CDH1 mutation. The genetic basis for the remaining cases of familial gastric
cancers are unknown, but likely involves mutations in other genes not yet identified
(Hansford et al., 2015). Mutations in MAP3K6 have also been implicated in families with
a strong history of gastric cancer, but its pathogenicity is questionable due to incomplete
variant segregation with disease and a high population frequency in databases like ExAc
(Volegaar et al., 2017). Several families meeting HDGC criteria have been found to have
pathogenic mutations in CTNNA1, which is in the same pathway as CDH1 (Volegaar et
al., 2017).
A new subsection of individuals without a family history of gastric cancer are
discovering their CDH1 mutations after undergoing multi-gene panel testing. Cancer
genetic testing has shifted drastically over the past several years, from targeted testing of
BRCA1 and BRCA2 alone, to testing large panels of genes associated with many different
types of cancer, including CDH1. These “incidental findings” of CDH1 mutation carriers
call into question the penetrance and cancer risks typically quoted, which were originally
calculated from families with a strong history of gastric cancer. Due to the rarity of the
condition, management recommendations are drawn from a limited number of patients. A
recent study sought to resolve this confusion by comparing patients with a CDH1
mutation undergoing PTG who met or did not meet testing criteria, finding that all
patients had early signs of gastric cancer regardless (Lowstuter et al., 2018).
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1.4 Total Gastrectomy
Patients who elect surgical intervention typically undergo a total gastrectomy with
esophagojejunal anastomosis and Roux-en-Y reconstruction. The esophagus is resected
above the gastro-esophageal junction and later reconnected to the small intestine after
removal of the stomach. Patients can still eat and drink, but typically eat smaller portions
throughout the day rather than the typical three meals. Depending on the surgical center,
patients also have the option of minimally invasive laparoscopic-approach as opposed to
a traditional open surgery (Strong et al., 2017).
Total gastrectomy is a major surgery, with physiological and psychological
recovery estimated to take approximately one year and additional complications
continuing throughout the rest of life (van der Kaaij et al., 2018). Strong et al. (2018)
reported postsurgical outcomes for 41 patients with a CDH1 mutation who underwent
PTG, finding a median length of hospital of seven days, with a range of four to 50.
Virtually all patients experienced substantial weight loss—about 15% of preoperative
weight—and 27% of patients had a complication requiring intervention. Pulmonary
complications, wound infections, and anastomotic leaks were also common. Despite the
common sequelae of surgery, almost all patients ultimately reported their overall outcome
“as expected” or “better than expected” (Strong et al. 2018).
Kaaij et al. (2018) also reported outcomes of PTG for 26 patients, finding that
postoperative complications occurred in 31% of patients, with 19% requiring surgical reintervention. Several patients were also readmitted to the hospital for nutritional and/or
psychosocial support within a year after PTG. Most individuals experienced dumping
syndrome post-surgery, which is caused by rapid entry of food into the small intestine
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and results in nausea, abdominal pain, diarrhea, and vomiting. For many patients,
dumping syndrome persists well after the estimated one-year recovery mark, in addition
to bile reflux and the use of pancreatic enzyme supplements. The rapid rise and then rapid
decrease of blood sugar can also cause weakness, sweating, and fatigue. Because food
bypasses the major sites for calcium, vitamin D, iron, and folate absorption in the
duodenum and jejunum, patients are at an increased risk of malnutrition, osteoporosis and
osteomalacia (Guilford et al., 2010).
1.5 The Psychosocial Impact
At-risk individuals are faced with difficult decisions about if and when to undergo
a prophylactic total gastrectomy, balancing the chance they may never develop cancer
with the limitations of endoscopic surveillance. Many have reported delaying the surgery
due to the complications such as weight loss, iron deficiency anemia, osteoporosis, and
rapid intestinal transit causing dumping syndrome (Muir et al., 2016). The psychological
impact of decisions regarding a prophylactic total gastrectomy is substantial.
Hallowell et al. (2016) interviewed individuals with HDGC about their decisionmaking process regarding a prophylactic total gastrectomy (PTG), finding that for some
individuals, coming to a decision about if and when to undergo surgery was difficult.
Uncertainty about the future and the development of cancer led some individuals to elect
for the PTG, while others felt the uncertainty influenced their decision to postpone
surgery until a positive biopsy result. Ultimately, individuals with HDGC are influenced
by multitude of factors in regard to their cancer surveillance, including objective
confirmation of cancer by positive biopsy, familial cancer burden, perceptions of post-
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surgical life, concerns that surveillance could miss a cancer developing, and the
individual’s life stage (Hallowell et al., 2016).
In the same study, Hallowell et al. (2017b) interviewed patients who had
undergone PTG and found that most reported surgery and recovery was easier than
anticipated, with younger patients reporting faster recovery times. However, many
struggled with body image issues and changing social, familial, and romantic
relationships in the aftermath of the surgery. These individuals reported feeling isolated
due to not being able to go out to eat or drink with friends, in addition to chronic fatigue
and a negative impact on sexuality. Ultimately, all interviewees viewed the benefits of
the risk reduction as outweighing the cost of surgery, but not without serious drawbacks
(Hallowell et al., 2017b).
Muir et al. (2016) also assessed overall well-being in patients who had undergone
PTG before and after their surgery, including standardized measures of health-related
quality of life (HRQOL), body image, psychological distress, regret, and decisional
conflict. Patients reported pain, fatigue, nausea, insomnia, dyspnea, and appetite loss two
weeks post-operation and did not reach baseline until one year after surgery. Notably,
half of patients expressed regret over having the surgery four weeks post-operation, but
this decreased to near zero over time. Most patients did not experience a substantial
change in body image and reported few symptoms of psychological distress. The most
pressing concern for the majority of patients was the drastic weight loss (Muir et al.,
2016).
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1.6 Emerging Adulthood
In the past, the transition between adolescence and adulthood was brief. Many
people entered the workforce immediately after finishing school, with marriage and
childbearing occurring shortly thereafter (Arnett, 2000). Widespread cultural shifts over
the past half-century have stretched this timeline for the majority of Americans. The US
Census Bureau reports the average age of first marriage for women and men respectively
has jumped from 21 and 23 in 1950, to 28 and 30 in 2018 (US Census Bureau, 2018). In
addition, the percentage of Americans with a bachelor’s degree or higher has increased
from less than 5% in 1940 to over 33% in 2016. The concept of a new, distinct life stage
between adolescence and young adulthood, deemed “emerging adulthood,” was proposed
by psychologist Jeffrey Arnett in 2000. Emerging adulthood spans the late teens through
the twenties and is characterized as a period of change and exploration of possible life
directions, before making enduring life decisions.
While it is widely recognized that the needs of children and adolescents vary from
adults in regard to healthcare and psychosocial support, the differing needs of emerging
adults is largely unrecognized. Epidemiologic studies have shown that 40% of emerging
adults in the USA meet criteria for a psychiatric disorder (e.g. anxiety and substance
misuse disorders), which is higher than every other age range (Arnett et al., 2014). For
emerging adults with a mental illness, receiving a diagnosis can contrast the individual’s
perception of their identity and reinforces a sense of abnormality (Arnett et al., 2014).
Similarly, individuals with HDGC may also struggle to cope with their cancer experience
during this unique period of identity exploration and instability.
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While no studies have specifically assessed emerging adults in regard to
hereditary diffuse gastric cancer, comparable studies have been done with another
hereditary cancer syndrome, Familial Adenomatous Polyposis (FAP). FAP is analogous
to HDGC in that it is a rare and highly penetrant hereditary cancer syndrome, typically
requiring prophylactic removal of the colon in adolescence or early adulthood.
Mireskandari et al. explored the psychosocial impact of FAP amongst 18- to 35-year-olds
by conducting in-depth interviews and found that the emerging adult population had
specific psychosocial needs and areas of concern. Participants disclosed numerous issues
regarding how FAP has impacted their life, including struggling with body image and
physical functioning as a result of surgery, anxiety about discussing FAP with new
partners, issues in relation to family planning, and a negative impact on employment. The
study concluded that longer-term support appears to be essential for this group of young
adults (Mireskandari et al., 2009).
Individuals with HDGC also face difficult decisions regarding planning a family.
As an autosomal dominant condition, there is a 50% chance for each pregnancy to be
affected. A study by Hallowell et al. explored the perceptions of individuals with HDGC
regarding reproductive decisions and family planning. Participant ages ranged from 1977, with a mean age of 40. Individuals who had completed childbearing prior to receiving
a diagnosis of HDGC expressed relief that they had not needed to consider this condition
prior to having children, as it may have affected the way in which they structured their
family. Regarding reproductive technology, the majority of interviewees were not in
favor of using prenatal diagnosis and subsequent termination of pregnancy. Many were in
favor of using pre-implantation genetic diagnosis to screen embryos, but voiced concerns
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about the cost and fail rate of in-vitro fertilization. Several participants anticipated
difficulty in communicating information about HDGC and about their risk to future
partners (Hallowell et al., 2017a).
Emerging adults with HDGC face numerous challenges, including the high risk of
developing cancer, invasive cancer surveillance measures, decision-making about a major
surgery with long-term complications, and the pain related to having relatives affected
with cancer and possible subsequent deaths. Evidence shows that young people are at
elevated risk of poor psychological adaptation to hereditary cancer syndromes, and
emerging adults with HDGC may have unique needs regarding psychosocial support
(Mireskandari et al., 2009). This study aims to explore the perspectives and experiences
of emerging adults to better characterize and identify unmet needs so that their healthcare
providers can better support them.
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CHAPTER 2
THE PERSPECTIVES OF EMERGING ADULTS WITH HEREDITARY DIFFUSE
GASTRIC CANCER1

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
1
Anderson, C., Jordon, E., Prose, A., Hallowell, N. To be submitted to Journal of
	
  
	
  

11

	
  
	
  
	
  
	
  
2.1 Abstract
Individuals with hereditary diffuse gastric cancer (HDGC) caused by a CDH1
mutation have a high lifetime risk of developing gastric cancer. National guidelines
recommend CDH1 carriers undergo a prophylactic total gastrectomy (PTG)— a surgery
that greatly reduces the risk of developing gastric cancer but has significant comorbidities. This study explores the impact of a diagnosis of HDGC in the transitional
life stage between the ages of 18-29 deemed “emerging adulthood.” We surveyed 21
CDH1 carriers and conducted semi-structured phone interviews with 6 CDH1 carriers
between the ages of 18-29 to learn about their life experiences regarding education,
career, relationships, and family planning. Participants were also asked about their
experience with genetic counseling. Specific challenges that were highlighted by
participants included time away from work due to doctors’ appointments and surgery
recovery, an impact on relationships with family and friends, and difficult choices
regarding family planning. Participants also struggle with the burden of being the expert
on their condition in relation to their friends and healthcare providers, though they find
support and knowledge in online groups for HDGC. These results demonstrate the
challenges of an HDGC diagnosis during emerging adulthood. Practice recommendations
for genetic counselors include providing HDGC-specific information for anticipatory
guidance, family planning options, and psychological health.
2.2 Introduction
Hereditary diffuse gastric cancer (HDGC) is a cancer predisposition syndrome
that confers up to a 70% and 56% lifetime risk of developing diffuse gastric cancer for
men and women respectively. HDGC is attributable to mutations in the E-cadherin gene
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(CDH1), which encodes epithelial cell adhesion proteins. Diffuse-type adenocarcinomas
are poorly differentiated and spread under histologically normal-looking mucosa without
forming a distinct mass, rendering endoscopic surveillance largely ineffective at detecting
this type of cancer in its early stages (van der Post et al., 2015). Many gastric cancers in
individuals with HDGC are diagnosed under age 40, with some occurring as young as the
mid-teens (Lynch et al., 2008). As such, CDH1 carriers are advised to undergo
prophylactic total gastrectomy (PTG) in their early to mid-20s—a key portion of a newly
recognized life stage deemed “emerging adulthood.” This time period between the ages
of 18 to 29 is marked by tremendous transition and growth (Arnett, 2000). As at-risk
individuals navigate completing their education, beginning a career and starting families,
they must also decide if and when to undergo PTG— recovery from which can take up to
a year or longer. As such, the physical and psychosocial burden of a diagnosis of HDGC
has significant implications for emerging adults, likely affecting areas of life including
education, employment, familial and romantic relationships, and family planning.
This study aims to explore the impact of this hereditary cancer syndrome during a
time of exploration and rapid transition through which emerging adults shape their lives.
A need exists for expansion upon previous studies on the psychosocial impact and
decision-making factors regarding the prophylactic total gastrectomy by assessing HDGC
in a broader context, including domains of life not limited to the surgery. Regarding
family planning, this study will assess similar perceptions as the Hallowell 2017a study,
while focusing specifically on the concerns of emerging adults, likely prior to starting a
family. In all, this study will explore the impact of HDGC regarding education,
employment, relationships, and family planning. To our knowledge, no other studies have
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addressed these themes in this population. The information gained from this study will
identify specific areas in which emerging adults with HDGC need support and provide
context to emerging adults’ decision-making regarding cancer management. Awareness
of the particular difficulties these individuals face may better prepare genetic counselors
and other healthcare professionals to identify these struggles and address unmet needs.
2.3 Materials and Methods
Participants
Participants included individuals between the ages of 18-29 with an identified
CDH1 mutation. Participants outside of this age range, in addition to participants who
had not had genetic testing or had received a Variant of Uncertain Significance, were
excluded from the study. Participants were recruited via an advertisement on the No
Stomach For Cancer Facebook page and other Facebook support groups. The
advertisement included a description of the study and a link to the confidential online
questionnaire. Participation was voluntary and respondents were not given any
compensation. The University of South Carolina Institutional Review Board (IRB)
deemed this study exempt from review in June 2018.
Materials/Measures
This study utilized mixed methodology consisting of a questionnaire and a semistructured interview. Mixed methods provided a comprehensive and more complete
understanding of each individual’s experience, with generalized data being collected
from the questionnaire and in-depth experiences gained from the interviews. The online
questionnaire contained questions about demographics, personal and family history of
cancer, and surgery status, in addition to experiences regarding education, career,
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relationships, family planning, and genetic counseling. The questionnaire was comprised
of multiple choice, Likert scale, and open-ended text entry questions. The semi-structured
interviews were conducted over the phone by a single researcher and included similar
themes as the online questionnaire. Additionally, phone interviewees were asked about
the impact on their overall life plans, their feelings upon diagnosis, and what information
they would like medical professionals and newly diagnosed HDGC patients to know.
Procedure
The questionnaire (Appendix B) was administered online through Survey Monkey.
The introduction to the questionnaire outlined the goals of the study and participants gave
their consent to participate by clicking “yes” to the first question. Participants were able
to skip any question or leave the questionnaire at any time. Because participants were
able to skip questions, there is variation in response rate. On average, respondents spent
13 minutes completing the questionnaire. Upon completion, respondents had the option
to provide their contact information for a semi-structured telephone interview. The
principal investigator (PI) contacted interested participants via email to determine a time
for the interview. Verbal consent for participation was obtained at the beginning of each
interview (Appendix C). On average, the interviews lasted 25 minutes (range 12-45
minutes). Interviews were recorded on the PI’s password protected computer and
transcribed verbatim.
Quantitative data were analyzed using SPSS statistical analysis software.
Analyses via descriptive statistics, reliability, and correlations were conducted as
appropriate. We analyzed the perceived impact of HDGC on education, career,
relationships, and family planning. The level of impact was assessed using a Likert scale
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(1=strongly disagree; 5=strongly agree) and were represented with descriptive statistics
(percentages and means). Qualitative thematic analysis was utilized to identify and
analyze reporting patterns within responses from open-text entry questions and semistructured interviews (Mays & Pope, 2000). After the raw data was read several times,
emergent themes were developed and grouped into categories based on their similarities.
Responses relevant to each category were examined using constant comparison, a process
in which each item is compared with the rest of the data to establish analytical categories.
Categories were added as needed to reflect the nuances of the data. Quotations were
extracted and classified to their corresponding theme and reported on their frequency.
Data was collected from September 2018 to January 2019.
2.4 Results
In all, 28 participants completed the online questionnaire and seven respondents
were excluded based on age or genetic testing status. Of the 21 eligible respondents, 16
(76.2%) were female, four (19.1%) were male, and one individual (4.8%) identified as
non-binary. The median age range of the participants was 24-26 years. Most (95.2%)
participants identified as Non-Hispanic White and one individual (4.8%) as
Hispanic/Latino. The majority (61.9%) of participants reside in the US, with some
(38.1%) participants residing outside the US in Canada and Europe (Appendix A). Six
participants also completed a follow-up telephone interview. Direct quotes are copied
verbatim from the open-text entry unless otherwise indicated to be from a telephone
interview.
Participants identified their CDH1 mutation status between the ages of 17-27,
with a median age of 21. Approximately one-third (33.3%) of participants indicated that
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they have had stage 1 stomach cancer cells on screening, eight (38.1%) had not, one
(4.8%) did not know, and five (23.8%) had not had any screening. Roughly half (47.6%)
of participants had their stomach surgically removed. Those who had their stomach
removed did so between the ages of 21-28, with a median age of 24.5. All participants
have a known family member with a CDH1 mutation. Almost all (95.2%) participants
reported they have a known family member with a CDH1 mutation who has had cancer
in the past. The most frequently reported type of cancer for these family members was
stomach, followed by breast and colon.
Education
Participant education level ranged from completion of high school to completed
master’s degree. The majority (71.4%) of participants continued their education beyond
high school (Appendix A). Participants ranked their level of agreement with different
statements addressing the impact HDGC has had on six aspects of their education.
Participants were most impacted in “the timing in which I pursued my education” and
“impacted what I chose to study” (mean=2.8; Figure 2.1). Several participants noted in
the open text-entry that they had completed their education prior to finding out their
mutation status or prior to pursuing PTG. Several respondents did note the need to take
time off school due to endoscopy screening procedures and impending surgeries. In
contrast, some respondents felt having HDGC has had a positive impact on their
educational goals, specifically in regards to pursuing a career in medicine:
“I found out about the CDH1 mutation and the resulting signet ring cells during
my A-levels; this severely affected my mental health and in turn affected my Alevel grades. I then took 2 gap years, before going to uni, to work on my mental
health… I now study BSc Biomedical Science and wish to pursue a career in
cancer research, particularly in digestive cancers. I am thriving at uni, gaining
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high 1sts in all modules and it is the motivation gained from my own experience
that is driving this.” — 21-23 y.o female (participant 1)
“It has interested me in other areas of medicine I had not considered and
strengthened my desire to go to medical school.” — 21-23 y.o. female (participant
16)
“I am a nursing student currently in school and am continuing my education
through the surgery and process. It makes me more motivated in ways but is
obviously hard knowing I have appointments and a large surgery.” — 21-23 y.o.
female (participant 9)
Career
Almost half of respondents are currently working in their career field (47.6%),
while others are currently working, but in a field they consider temporary (14.3%). For
reasons unrelated to HDGC, 28.6% of individuals report not working. The questionnaire
asked participants to rate their level of agreement with different statements addressing the
impact HDGC has had on six aspects of their career. Participants were most impacted in
“caused me to take off work” (mean=3.7; Figure 1.2). Approximately one-third of
participants (31.6%) felt that HDGC had influenced their choice of career and 45%
agreed that HDGC affected their job performance. Over half (52.6%) of participants
agreed that they had taken time off work for HDGC-related reasons. In the open-ended
text entry, several participants cited negative impacts on their career in regards to PTG
and recovery:
“I'm currently in training for a new career and awaiting surgery so it will impact
my career drastically as I will be needing time off and will not be eligible for
benefits as a new employee.” — 24-26 y.o. female (participant 14)
“It was a full 6 months before I was physically ready to step back into a part time
position. Now at a year post I'm working full time and feel strong. My several
month hiatus definitely impacted my position, job, and relevance in a small
growing company.” — 27-29 y.o. male (participant 4)
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“I'm self employed - but have reduced my working hours to recover. I feel that
eating is a full time job and my day revolves around that.” — 27-29 y.o. female
(participant 18)
Other participants felt that HDGC has not negatively affected their career and, in some
cases, motivated them more:
“I have had to take time off to attend testing and treatment. But other than that I
don't feel it has affected my work.” — 27-29 y.o. female (participant 20)
“Although I have to take frequent time off work for surveillance endoscopies,
having HDGC does not affect my work in a negative way. It is only making me
want to work harder to be able to get to where I want to be for my future career:
in cancer research.” — 21-23 y.o. female (participant 1)
Relationships with romantic partners, family, and friends
In regards to romantic relationships, participants were either single (23.8%), in a
committed relationship (28.6%), or married (33.3%). The questionnaire asked
participants to rate their level of agreement with different statements addressing the
impact HDGC has had on six aspects of their romantic relationships. Overall, participants
disagreed with the idea that HDGC impacted their romantic relationships. The statement
that most closely approached “neither agree nor disagree” was in regard to “going out on
dates and other social activities” (mean=2.6; Figure 2.3). Many respondents in committed
relationships or married found their partners to be a source of support. Several single
respondents had concerns about meeting potential partners, especially related to PTG:
“I have been nervous about dating and seeking out partners since my surgeries
(mastectomy and TG).” — 21-23 y.o. female (participant 16)
“It hasn't impacted it through diagnosis only but I anticipate it affecting
relationships after surgery.” — 24-26 y.o. female (participant 14)
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Figure 2.1 Impact on Education. Participants’ perceptions of the level of impact HDGC
has had on their education (1=strongly disagree; 5=strongly agree).
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“It was hard telling someone at first and possible prospect of our future children
carrying this gene is something we will need to deal with.” – 27-29 y.o. female
(participant 5)
Participants overwhelmingly (100%) felt supported by their families in regards to
their HDGC diagnosis. The questionnaire asked participants to rate their level of
agreement with different statements addressing the impact HDGC has had on six aspects
of relationships with family members. Respondents expressed the highest level of
agreement to “living with HDGC has helped me know who I can count on in times of
trouble” (mean=4.7; Figure 2.4). In describing their relationships, many participants
noted the positive impact HDGC has had on their family:
“Amazing family and friend support. Made me so appreciative of the people I
have in my life.” — 27-29 y.o. female (participant 5)
“It has made us stronger and more closer as a unit.” — 27-29 y.o. female
(participant 6)
Some participants specifically cited the support and understanding of family members
who also have HDGC:
“It helps having family members who have successfully went through surgery and
who now for the most part lead relatively normal lives. They keep me positive.”
— 24-26 y.o. female (participant 14)
Despite the positive aspects of familial relationships, 44% of participants felt HDGC had
caused tension and strained relationships in the family. This tension was often related to
difficulties in communication and differences in risk perception:
“Me and my mother have formed a stronger bond, but I feel relationships are a bit
strained in my dad's side of the family where the CDH1 mutation is. It's like an
elephant in the room that some people don't want to discuss or face.” — 27-29 y.o.
female (participant 18)
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“My family is very supportive of my diagnosis except one sister in law who
believes genetics have nothing to do with cancer and it’s our thoughts that give us
cancer, so my gastrectomy was pointless.” — 27-29 y.o. female (participant 17)
“Some family members disapprove of my medical choices, while others stand by
me.” — 21-23 y.o. female (participant 16) left
The questionnaire also asked participants to rate their level of agreement with
different statements addressing the impact HDGC has had on six aspects of their
friendships. Participants expressed the highest level of agreement with, “I feel supported
by my friends in regard to HDGC” and “living with HDGC has helped me know who I
can count on in times of trouble” (mean=4.2; Figure 2.5). In general, participants felt that
their friends are supportive, but do not fully understand HDGC:
“It has created distance with some friends who don't know what to say or do,
while strengthening the bond with some of my closest friends.” — 27-29 y.o.
male (participant 4)
“My friends have been supportive however it is something that can be rather hard
to comprehend. So I feel more support from my family opposed to friends.” —
24-26 y.o. female (participant 14)
“All my friends know for the most part, they're overall really supportive. Some of
them don't, I don't think fully understand, and not in a malicious way, but…
they're kinda like, ‘oh, you're so skinny, you're so lucky.’ And it's like, okay, well
no.” — (participant 8, phone interview)
“I think it's really difficult for people to understand what this is because it's not
saying I have cancer. It's saying I could. And people aren't used to absorbing that
kind of information. So the fact that it's not really a straight forward diagnosis…
the level of sympathy is not always there.” — (participant 26, phone interview)
Half of respondents (50%) agreed with the statement “living with HDGC has caused me
to miss out on social activities.” Respondents described their struggles with eating and
drinking out with friends after PTG:
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Figure 2.3 Impact on romantic relationships. Participants’ perceptions of the level of
impact HDGC has had on their relationships with romantic partners (1=strongly
disagree; 5=strongly agree).
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Figure 2.5 Impact on friendships. Participants’ perceptions of the level of impact
HDGC has had on their friendships (1=strongly disagree; 5=strongly agree).
“There's been times where I've had to leave a social event early because I've been
feeling ill, and especially now for going out for meals with people. I don't feel
very comfortable doing that right now.” — (participant 18, phone interview)
“Exhausted, ‘grumble guts’, and never sure of how much energy I would have
tomorrow made me a no show more often than not to most activities including
family gatherings and friends nights out.” — 27-29 y.o. male (participant 4)
Family Planning
The majority of respondents (83.3%) did not have children. For the three
individuals that have children, one had children prior to being diagnosed with HDGC and
all individuals had their children naturally without using assisted reproductive techniques.
In planning for the future, one individual plans to have more children, and two are
undecided. For the respondents without children, 66.7% (n=10) plan to have children in
the future, 26.7% (n=4) are undecided, and 6.7% (n=1) do not plan on having children.
Of those who plan to have children in the future, 63.6% have considered having children
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naturally, 54.6% have considered pursuing IVF and PGD, 27.3% have considered
adoption, and 9.09% have considered using a donor egg or sperm (Figure 2.6). When
asked to what extent HDGC has influenced the participants’ position on having or not
having children, the majority of participants (55.1%) chose “a moderate amount” or
above (weighted average 3.1). Several participants expressed their desire to have children
naturally, without technological intervention:
“It changes nothing. I will never ‘pick’ a child out of my eggs. If my parents had
that ‘option’ and if they knew...I wouldn’t be here. I will have a kid and we will
live this life.” — 27-29 y.o. female (participant 6)
“IVF was not for me. I trusted I would get the children that were meant for me
naturally.” — 27-29 y.o. female (participant 17)
“When I first got my diagnosis I felt terrible that I could have possibly passed this
on to my daughter. And I really questioned having more children… But after
talking with my fiancé and family and doctors, they have all encouraged me to
pursue in whichever direction I want. That I shouldn't let my diagnosis determine
everything in my life.” — 27-29 y.o. female (participant 20)
In contrast, other respondents expressed discomfort and fear at the possibility of their
children inheriting the mutation, while expressing varying levels of comfort with the idea
using IVF and PGD:
“I feel almost irresponsible if I have children biologically mine because I don’t
feel comfortable with PGD. It’s a big gamble, and I’m not sure how I feel yet.” —
21-23 y.o. female (participant 16)
“It has affected me so much, I don’t want the possibility of me passing this
genetic mutation on to my babies.” — 18-20 y.o. female (participant 24)
“The reality of CDH1 means that there is no way I will have biological children I can't risk passing it on… the chance of me dying young is too high… I can't
have kids knowing how likely it is that they would have to go through that.” —
27-29 y.o. non-binary (participant 27)
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“I think it's a lot more to sign up for. I think if I were to have children, and I'm
currently undecided, it would be through IVF. So it's a big decision in a sense. I
won't pursue having children naturally.” — (participant 26, phone interview)
Several participants’ concerns were largely due to the potential complications of
pregnancy after surgery:
“I wouldn't not have children in fear of the mutation I just worry about the
complications that may arise with having a child after surgery.” — 24-26 y.o.
female (participant 14)
“Has not influenced my family planning except when will be the right time to do
the full gastrectomy.” — 21-23 y.o. female (participant 11)
Participants also expressed hope and expectation in advancements in medical technology
and cancer prevention techniques:
“I see it as if my child has this gene, then with how far the medical world has
come in 20 years, by the time by child is 18 we could be even more advanced than
what we are now...” — 27-29 y.o. female (participant 5)
“The next few years will tell us a lot about genetics and its impact on us as a
species going forward. Crisper could make this discussion null and void inside of
a few decades.” — 27-29 y.o. male (participant 4)
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Figure 2.6 Methods of reproductive planning considered by respondents.
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Genetic Counseling
Almost all respondents (95%) were seen by a genetic counselor regarding their
diagnosis of HDGC. Many respondents (78%) found their genetic counselor to be very
useful or extremely useful and agreed (89%) that the genetic counselor had provided
them with the appropriate amount of information. Two participants noted negative
aspects of their genetic counseling experience in the open-text entry: one felt the genetic
counselor had not provided them with information they did not already know from family
members, and one was upset with the manner in which they received their results (i.e.
voicemail). However, most responses were positive and noted the support and
information provided by the genetic counselor:
“We met with the genetic counselor while also with the surgeon who would later
perform my mother's gastrectomy. The surgeon asked me some question about
children, and I said something along the lines of ‘well, I'm obviously not having
kids now.’ He acted like what I had said was bizarre or unexpected. The genetic
counselor, however, didn't seem surprised and clearly understood where I was
coming from. That has stuck with me.” — 27-29 y.o. non-binary (participant 27)
“She told me a lot of information that I didn't already know. I think I only had 1
session with her but she did give a lot of info and was useful.” — 27-29 y.o.
female (participant 5)
Overall quality of life
Four additional themes emerged from participants’ responses during the semistructured phone interviews and open-text entry questions: (i) the burden of being the
expert on HDGC, (ii) the significant impact on mental health, (iii) the use of online
communities as a source of support, (iv) and a positive outlook on overall quality of life.
Due to the rarity of HDGC, participants felt frustrated explaining their condition
to friends and family members:
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“When you tell them, "my mom doesn't have a stomach," it's kind of a shock. So
it's like, people think you can't live without it or something. It's just something
that's really hard to explain. So I don't even really go into big detail about it.” —
(participant 14, phone interview)
“I wish there was a like a pamphlet, like an easy, digestible pamphlet, to give to
family and friends. It's been years and there's no easy or short way to explain it.
And it takes a lot of discussion to understand.” — (participant 26, phone
interview)
Participants also expressed frustration with the burden of educating their own healthcare
providers on the condition, and sometimes feeling misunderstood:
“Even at the dentist they ask you to explain your last hospital procedure. So I'm
sitting there for 5 to 10 minutes explaining to a dental hygienist what I have
wrong with me. It never gets easier.” — (participant 26, phone interview)
“Being someone in the medical profession as well, it just surprises me sometimes
how much a lack of compassion some providers can still have and they are just
like, ‘what? a total gastrectomy? what?’” — (participant 8, phone interview)
“[Describing a nurse] Right after I woke up from my endoscopy, she said ‘so
you're going to get the gastrectomy, you've already decided?’ I said ‘yeah, I'm
going to get it.’ She was like, ‘but you're so young, have you thought about this,
have you thought about this?’ And I was super irritated because she knew
nothing… it made me so nervous. I had just woken up from the procedure.” —
(participant 9, phone interview)
Several participants struggled with their mental health at various stages in their
journey through diagnosis and after PTG. One participant described an onset of anxiety
attacks after finding out about her carrier status and ended up seeking help through
therapy and medication. Others described serious mental health struggles throughout
surgery recovery, both as a result of burdensome physical symptoms, as well as the
perceived effect of removing the stomach on brain chemistry:
“I think the psychological impact is not discussed. Finding out about the mutation
was difficult enough, but life post gastrectomy is mentally challenging. I'm aware
serotonin is released in the gut and the whole system has changed, which disrupts
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this. I think there should be more support offered afterwards.” — 27-29 y.o.
female (participant 18)
“Emotional health during this procedure was hell. Your brain chemistry is so
messed up when you remove your gut and ability to process food they way your
body has known. New normal is different and good but takes months to achieve.”
— 27-29 y.o. male (participant 4)
“Anxiety attacks, medication, seeing a therapist… I feel like I'm sinking half the
time but I mean at the end of the day, I mean I'm so lucky to be able to get this
surgery and to have a healthy long life after that… but I can't really control the
way I feel now.” — (participant 9, phone interview)
While struggling with the rarity of the condition and lack of awareness in the
general public, participants found comfort and support in online communities for HDGC.
They also used these communities as a major source of knowledge regarding cancer risks
and surgery:
“It was crucial that I learn about it, especially for where I live. I’ve literally never
met anyone in person that has what I have. It's only been online. Yeah it's been
valuable but it's also very much normalized this whole thing.” — (participant 26,
phone interview)
“I researched a lot [before surgery] and I'm in a few groups online. That helps me
with things with like nutrition and vitamins and all these things I didn’t
necessarily know about that are important.” — (participant 18, phone interview)
In response to a question about the impact of having a CDH1 mutation on overall
quality of life, the majority of respondents (56.3%) had a positive outlook. Respondents
felt empowered by the knowledge of this mutation and the option to reduce their cancer
risk:
“Before my gastrectomy I was riddled with anxiety knowing I had that ticking
time bomb inside of me. I spent every family event in my head thinking I need to
make it perfect in case this is my last whatever holiday we were celebrating. It
was awful. Now I have more peace while celebrating these, and just have to watch
everyone eat their good foods and treats I can no longer tolerate.” — 27-29 y.o.
female (participant 17)
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“My life has changed forever but I have no regrets. I've seen what stomach cancer
does and how quickly it takes away a person. I need time to adjust to a new
normal. I feel hopeful that I'll get there!” — 27-29 y.o. female (participant 18)
Participants also felt hopeful for the future:
“I think it has opened my eyes to living in the moment and being grateful for
what's around me and the people I have. It affected me negatively just in the
beginning. But now I am optimistic for what the future holds.” — 27-29 y.o.
female (participant 20)
“It has made it better. I am more aware of everything. Yes I have the down days
but man those days make me feel so blessed to be alive. Now don’t get me wrong.
Not having a stomach can suck. Cancer sucks… but my quality of life is beautiful.
And even on the hard days it still is.” — 27-29 y.o. female (participant 6)
In contrast, several respondents (18.8%) cited the negative impact their CDH1 mutation
has had on overall quality of life:
“Yes— it is emotionally and physically very draining.” — 24-26 y.o. female
(participant 8)
“Yes 100%, my eating, exercise, sleep, etc!” — 18-20 y.o. female (participant 24)
Throughout open-text entry questions and semi-structured phone interviews, participants
demonstrated a strong sense of positivity and resiliency. When asked what advice they
would give to someone recently diagnosed with HDGC, many participants emphasized
how fortunate they feel to have this information and that this diagnosis doesn’t define
their life:
“My token phrase is that everybody's dealt a certain hand of cards and it's how
you play them. I think you can look at this as a negative, especially for someone
that had no idea this was coming. But I'm really lucky that I [found out about the
mutation] because I wouldn't have been here in 5, 10, 20 years… it's not always
that bad. I'm lucky to know this is here and taking the steps and taking control of
my own health.” — participant 26, phone interview
“…it's not as scary as it initially sounds and it doesn't affect your life in a horribly
dramatic way. You just eat smaller amounts of food and you continue on. It's
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basically it's not as life-altering and as scary as you first think when you hear an
organ is going to be removed entirely.” — participant 20, phone interview
“I simply want people to know that there is life after a total gastrectomy. Because
you know, when I when I initially found out about all of this, I had no idea that
people could even live without a stomach. I thought that was crazy. It's possible
and it's not as hard as it seems.” — participant 18, phone interview
2.5 Discussion
This study explored the perspectives of emerging adults (ages 18-29) with a
CDH1 mutation to gain a better understanding of how they are impacted by their carrier
status in multiple domains of life: education, career, relationships, and family planning.
In addition, we assessed experiences and satisfaction with genetic counseling, as well as
perceived overall impact on quality of life. Specific challenges highlighted are missed
time at work, strained familial relationships, difficult reproductive decision-making,
mental health struggles, and the burden of being the expert on HDGC. Despite these
challenges, many participants felt empowered by knowing their mutation status and had a
positive outlook on life. They found support in their partners, family and friends, and
online support networks.
Education and Career
The greatest challenge participants faced in terms of their career was prolonged
absence due to surgery and recovery. After returning to work, participants struggled with
fatigue and other post-PTG side effects, which in turn affected performance and
attendance. One participant anticipated not being able to return to work full-time as a
nurse due to the physical demands of the job, and another reduced her working hours
because her day now revolves around eating. These sentiments support findings by
Hallowell et al., which found that individuals who had undergone PTG in their early 20s
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struggled with feeling left behind in their career as a result of time lost due to surgery and
recovery. Additionally, interviewees of all ages cited fatigue as a major issue after
surgery that prevented them from returning to work full time (Hallowell et al., 2017b).
Participants were less impacted by HDGC in terms of their education, as
evidenced by the lower level of impact across all six categories. One contributing factor
to this result may have been the significant number of respondents who finished their
education prior to finding out their CDH1 mutation status. In addition, two participants
with impending surgeries noted that while HDGC had not yet impacted their education,
they anticipated taking time off for recovery in the future. Of note, several participants
found their mutation status to be motivation for their education, as opposed to a
hindrance. This is demonstrated by the multiple respondents who cited their experience
with HDGC as inspiration for their ambitions in medicine and science.
Relationships with family, friends, and romantic partners
As a whole, relationships with family, friends, and romantic partners were
supportive and helpful to respondents. Participants felt most supported by their family
members, especially those with HDGC, as they were able to share unique experiences
and information with one another. Previous research has found that the experience of
having close relatives with cancer can serve as a catalyst for positive changes in behavior,
such as revising life priorities and maintaining closer relationships with family in general
(McPhail et al., 2016). The participants in this study demonstrate a similar phenomenon,
as all participants indicated a known family member with an HDGC-related cancer. In
addition, a study by Kenen et al. described participants who felt comforted to share a
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BRCA1/2 mutation with family members because it became something they could then
cope with as a unit (Kenan et al., 2006).
Despite feeling supported by family in general, participants also felt at odds with
some family members regarding their healthcare decisions. Nearly half of respondents
(44%) felt HDGC had caused tension and strained relationships in the family, often times
due to difficulties in communication and differences in risk perception. These results
were similar to the findings of Douglas et al., whose participants with a BRCA1/2
mutation felt more or less connected to certain family members depending on family
cancer history, communication patterns, and mutation status. While sharing a mutation
with relatives often created a special bond, there was also tension when family members
perceived their cancer risk differently or made contrasting decisions regarding
surveillance measures (Douglas et al., 2009). These results further demonstrate that a
diagnosis of a cancer-predisposition syndrome involves the family rather than the patient
alone.
Regarding friendships, participants largely felt supported by their friends while
simultaneously struggling with their lack of understanding about the condition. Going
through this experience created distance in some friendships, which participants
perceived as their friends not knowing what to say rather than not caring. Participants
who had undergone PTG also cited difficulty making plans with friends, especially
involving eating or drinking. This sentiment was mirrored in romantic relationships, in
which the highest level of impact ranked by participants was “going out on dates and
other social activities.” Furthermore, single participants experienced anxiety about being
with someone new post-PTG and anticipated difficulty in relaying their recurrence risk to
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a future partner. These results support findings by Mireskandari et al., which found that
young adults with FAP avoided intimate relationships as a result of low self-esteem from
surgery scars and changing body image post-surgery. In addition, single young adults
with FAP felt apprehensive about discussing the possibility of passing FAP on to future
children (Mireskandari et al., 2009).
Family planning
Reproductive decision-making in the context of cancer risk is complex, and
participants demonstrated mixed feelings regarding future family planning. When asked
which methods of conception they had considered for the future, the highest percentage
of participants considered conceiving naturally, followed closely by pursuing IVF with
PGD. While many participants felt a responsibility to avoid passing on a CDH1 mutation
to their children, a minority were interested in pursuing options to have non-biological
children via adoption or egg/sperm donation. Participants expressed varying levels of
comfort with the use of reproductive technology. Several participants were adamantly
against PGD and felt that screening embryos invalidated the value of their own existence
as a person with HDGC. Others would not consider having biological children at all
without ensuring they would not have the mutation. Ormondroyd et al. found a
comparable range of opinions when interviewing women diagnosed with a BRCA1/2
mutation prior to having children. Several interviewees expressed uneasiness with the
thought that perhaps they would not exist if their parents had the same reproductive
screening options, while others believed they had a moral responsibility to ensure the
mutation was not passed down to the next generation (Ormondroyd et al., 2012).
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A common theme among many participants considering natural conception was
the hope or expectation that future developments in medical technology will render this
discussion null and void for their children. Previous research has highlighted a similar
sentiment reported by young, female BRCA1/2 carriers, some of who held strong beliefs
that new treatments and preventive measures will be more successful for their children
(Donnelly et al., 2013). In addition, female participants struggled with the logistics of
balancing the need for risk-reducing surgery (gastrectomy and/or mastectomy) and the
timing of pregnancy. Several of these themes were reflected in a 2017 study by Hallowell
et al., in which interviewees expressed a spectrum of opinions on reproductive options for
CDH1 carriers. While the majority of childless interviewees were unsure of whether to
pursue reproductive testing, many were open to the idea of utilizing IVF with PGD to
screen embryos (Hallowell et al., 2017a). These results reflect the diversity of views held
by emerging adults when considering family planning and highlight the critical need for
reproductive counseling.
Genetic Counseling
Genetic counselors are trained to provide education on the genetic basis of disease
and recurrence risk, in addition to assessing the psychosocial needs of each patient
(Schneider, 2012). Almost all participants in this study were seen by a genetic counselor
when being tested for a CDH1 mutation. The majority of participants felt their genetic
counseling session was useful and that they were provided with the appropriate amount
of information. Several participants also mentioned feeling compassion and
understanding from genetic counselors specifically, sometimes in contrast to other
healthcare providers. These results suggest that in the context of counseling for HDGC,
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genetic counselors should continue to approach patients with compassion and empathy, in
addition to providing resources to support organizations. Genetic counselors should also
be mindful to ask patients how they would like to receive their results and accommodate
patients accordingly (Schneider, 2012).
Living with a rare condition
Due to the rarity of HDGC, participants often felt frustrated with the
responsibility of explaining this condition to others. They found people were unfamiliar
with the concept of cancer predisposition in general and skeptical about the possibility of
living without a stomach. As a result, they often respond with incredulity rather than
sympathy. Participants desired an accessible resource such as a pamphlet or booklet that
they could give out rather than attempting to explain the condition themselves.
Respondents were especially burdened by a lack of knowledge among their own
healthcare providers and utilized online communities for medical information and
surgeon recommendations. Additionally, online networks such as No Stomach For
Cancer and Facebook support groups helped lessen the feeling of isolation among
respondents, connecting them over long distances and providing a sense of community.
Similarly, Ross et al. found that online blogs functioned as a means to connect
individuals in the FAP community. Much like the responses from emerging adults with
HDGC, FAP bloggers noted the poor understanding of their condition amongst medical
professionals and within their social circles. Bloggers utilized their online space to share
their own experiences and provide advice to others with the condition (Ross et al., 2018).
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Mental health & overall well-being
Several participants struggled with their mental health at various stages in their
journey through diagnosis and after PTG. Prior research studies have demonstrated that
approximately 40% of emerging adults in the USA meet criteria for a psychiatric disorder,
most commonly anxiety or substance abuse (Arnett et al., 2014). Given this background
risk, emerging adults dealing with the added stress of cancer risk and major surgery may
have an increased risk of developing a mental illness. Several participants described
serious mental health struggles throughout surgery recovery, both as a result of
burdensome physical symptoms, as well as the perceived effect of removing the stomach
on brain chemistry. These responses highlight the need to discuss the psychosocial
implications of surgical recovery earlier in the decision-making process, in addition to
following up with patients long-term after surgery.
Despite the psychological impact of HDGC, respondents had an overwhelmingly
positive response when asked how this condition had impacted their overall well-being.
Many expressed how thankful they are to have found out about their carrier status at all.
They find it empowering to be able to take steps to reduce their cancer risk, either by
surveillance or undergoing surgery. Previous research on the psychosocial impact of
undergoing PTG has found relief of anxiety regarding gastric cancer risk to be a major
benefit of undergoing surgery (Hallowell et al., 2017b). This sentiment mirrors the
participants of this study, many of whom perceived the option of risk-reducing surgery to
be a positive step in managing cancer risk. In addition, participants noted the unique
perspective they have gained from having a family history of cancer and facing their own
cancer risk. A theme of positive personal outcomes has previously been reported in
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individuals with a family history of cancer, in which interviewees discussed having
greater maturity and compassion, as well as maintaining a perspective on the important
things in life (McPhail et al., 2017). Similarly, participants in this study were well
adjusted to their diagnosis and had a positive outlook for the future.
Practice Implications
It is critical that healthcare providers take a holistic approach in the care for
emerging adults with a CDH1 mutation. Given the results of this study, providers should
recognize the unique challenges that come from a diagnosis of HDGC in the context of
the individual’s stage of life. Below are practice recommendations for genetic counselors
and other providers caring for the HDGC population based on the results of this study:
1. Genetic counselors should consider the needs of the emerging adult
demographic as they provide anticipatory guidance for managing all aspects
of the condition. This guidance includes recognizing the potential impact on
education, career, and relationship-dynamics.
2. Genetic counselors should be prepared to present all reproductive options to
individuals with HDGC. This not only includes counseling on recurrence risk
and assisted reproduction therapies but also includes being able to address
childbearing pre- vs. post-gastrectomy. Structured follow-up or referrals may be
helpful to readdress family planning as individuals and couples consider these
decisions over time. In addition, information regarding pregnancy after PTG is
available through No Stomach For Cancer.
3. Genetic counselors and other providers should be aware of and continue to
develop resources for individuals with HDGC. As healthcare providers
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specially trained to communicate complex genetic concepts, genetic counselors
are in a unique position to find or create the educational materials desired by
patients with HDGC to give to family, friends, and healthcare providers.
Emerging adults should also be made aware of networks such as No Stomach For
Cancer, which many participants cited as a significant source of support and
information.
4. Genetic counselors should recognize and address the significant
psychological impact of this diagnosis and encourage referrals to mental
health services. This is needed especially for emerging adults given the
background risk of a psychiatric disorder.
Limitations and Future Research
The results of this study are limited by a small sample size (n=21), which
inhibited accurate comparisons between groups (e.g. pre- or post-PTG, single vs.
married). In addition, our demographics were heavily skewed towards female and
Caucasian participants and cannot be generalized to ethnic minority or male CDH1
carriers. Lastly, participants were recruited through international support networks and
the results are limited to the reflections of individuals connected to the support groups
through Facebook. It is possible this sample represents CDH1 carriers that are
exceptionally motivated to act or to seek help, with increased access to educational
materials through the connections to online communities. Differing opinions and
additional themes may arise from emerging adults with HDGC who are not connected to
online support groups. We believe that a similar study with a larger sample size may
yield a more diverse participant population and statistically significant results when
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comparing between groups. Alternate methods of recruitment, such as through a medical
system as opposed to support groups, could also give rise to different viewpoints.
Furthermore, it is possible the perspectives captured in this study are representative of a
broader age range of individuals with HDGC, rather than emerging adults only.
Additional research is needed to assess the impact of HDGC in individuals of all ages.
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CHAPTER 3
CONCLUSIONS
This study explored the perspectives of emerging adults with a CDH1 mutation to
gain a better understanding of how they are impacted by their carrier status in multiple
domains of life: education, career, relationships, and family planning. We also assessed
experiences and satisfaction with genetic counseling and overall quality of life. Specific
challenges highlighted were missed time at work, strained familial relationships, difficult
reproductive decision-making, mental health struggles, and the burden of being the expert
on HDGC. Despite these challenges, many participants felt empowered by knowing their
mutation status and had a positive outlook on life. They found support in their partners,
family and friends, and online support networks. The results of this study provide a
glimpse into the lived experience of emerging adults with hereditary diffuse gastric
cancer and distinguish the unique needs of these individuals after diagnosis. While
HDGC is rare, genetic counselors will increasingly interact with patients receiving
positive results for a CDH1 mutation as the utilization of multi-gene panels for oncology
testing continues to increase. Overall, a need exists to raise awareness of HDGC and have
educational materials in place so this information is conveyed effectively to healthcare
providers. In addition, it is critical that healthcare providers take a holistic approach in the
care for emerging adults with a CDH1 mutation. While providing the appropriate medical
treatment and guidance, providers should be sensitive to patients’ informational and
psychosocial needs in the midst of rapid social and professional development.
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APPENDIX A
DEMOGRAPHIC TABLE

Characteristics
Gender
Age (years)

Ethnicity
Highest level of
education

Region of residency

	
  

Response
Male
Female
Non-binary
18-20
21-23
24-26
27-29
White or Caucasian
Hispanic/Latino
Completed high school
Some college
Trade/technical/vocational training
Bachelor’s degree
Master’s degree
United States
International

46

n
4
16
1
2
4
5
10
20
1
4
5
2
6
2
13
8

(%)
19.0
76.2
4.8
9.5
19.0
23.8
47.6
95.2
4.8
19.0
23.8
9.5
28.6
9.5
61.9
38.1

	
  
	
  
	
  
	
  

APPENDIX B
ONLINE QUESTIONNAIRE
Hello,
Thank you for participating in my graduate research study. The goal of this study is to
gather information about what life is like for individuals aged 18-29 with a CDH1
mutation. We are curious about multiple areas of your life including education,
employment, and planning a family. We would also like to know how Hereditary Diffuse
Gastric Cancer (HDGC) has impacted your relationships with family, friends, and
partners. Your answers will help genetic counselors, doctors, and other healthcare
providers better support and care for patients who have HDGC.
Important things to know about this study:
•

•
•
•
•

The survey is open to anyone currently aged 18 to 29 who has a CDH1 mutation.
We also ask that you encourage eligible family members and/or friends to take the
survey.
The survey will take approximately 20 minutes to complete.
The survey is anonymous and participation is voluntary.
You can skip any question(s) you are not comfortable answering and may exit the
survey at any time.
The survey will be available until January 31, 2019.

This study was reviewed and approved by the University of South Carolina Institutional
Review Board. If you have any questions about this research project, please contact
Carrie Anderson at carrie.anderson@uscmed.sc.edu, or the University of South Carolina
faculty advisor, Emily Jordon, at emily.jordon@uscmed.sc.edu
Thank you again for your time and participation!
Sincerely,
Carrie Anderson
MS candidate in Genetic Counseling
University of South Carolina, School of Medicine
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Hereditary diffuse gastric cancer (HDGC) is an inherited cancer syndrome that increases
the chances of developing both diffuse gastric cancer and lobular breast cancer.
“Hereditary diffuse gastric cancer” is the name of the syndrome. People who inherit the
CDH1 mutation are considered to have HDGC, even if they themselves have not
developed cancer.
1. By clicking “Yes,” you consent to participate in our study.
a. Yes
b. No [if no is selected, skip to end of survey]
2. Are you currently between the ages of 18-29 years?
a. Yes
b. No [if no is selected, skip to end of survey]
3. How old are you?
a. 18-20
b. 21-23
c. 24-26
d. 27-29
4. Which of the following best represents your race/ethnicity?
a. American Indian/Native American
b. Asian
c. Black/African American
d. Hispanic/Latino
e. Native Hawaiian/Pacific Islander
f. Non-Hispanic White
g. Other (please specify): _____
5. Which of the following do you identify as?
a. Female
b. Male
c. Prefer to self-describe: ______
6. In which country do you live?
a. USA
b. Other (please specify) ______
7. [If “USA” to Q6] In which state do you live: _______
8. Have you had genetic testing for HDGC?
a. Yes
b. No [skip to end of survey]
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9. [If “yes” to Q8] What was the result of that test?
a. Positive (you have an identified CDH1 gene mutation)
b. Negative (you do not have a CDH1 gene mutation) [skip to end of survey]
c. Uncertain result (variant of uncertain significance, VUS) [skip to end of
survey]
The following set of questions will ask you about your own medical history and your
family history in relation to Hereditary Diffuse Gastric Cancer (HDGC).
10. How old were you when you had genetic testing for a CDH1 mutation? ___
11. Have any of your relatives also tested positive for a CDH1 mutation? Please select all
that apply
a. I am the only person in my family who has tested positive for a CDH1
mutation
b. Yes, my mother/father has a CDH1 mutation
c. Yes, my sibling(s) has/have a CDH1 mutation
d. Another relative has a CDH1 mutation. Please list all other relatives with
HDGC (for example: cousin, aunt, etc): _______
12. Have you ever been found to have stage 1 stomach cancer cells (signet ring cells) on
screening?
a. Yes
b. No
c. I have not had any screening
d. I don’t know
13. [If “yes” to Q12] How old were you when you were first found to have stage 1
stomach cancer cells _______
14. Have you had your stomach surgically removed?
a. Yes
b. No
15. [If “yes” to Q14] How old were you when you had your stomach removed? ______
16. Have you ever been diagnosed with cancer?
a. Yes
b. No
c. I don’t know
17. [If “yes” to Q16] With which type of cancer were you diagnosed? Please choose all
that apply.
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a) Stomach
b) Breast
c) Colon
d) Other (please specify): _______
18. [If “yes” to Q17a] How old were you when you were first diagnosed with stomach
cancer? ______
19. Have any of your family members or relatives with a CDH1 mutation ever been
diagnosed with cancer?
a. Yes
b. No
c. I don’t know
20. [If “yes” to Q18] Please specify which of your relatives with a CDH1 mutation have
been diagnosed with cancer and with what type.

Stomach
cancer

Breast cancer

Colon cancer

Mom / Dad
Brother(s)
Sister(s)
Grandparent(s)
Aunt(s) / Uncle(s)
Cousin(s)
21. [If “yes” to Q17] Have any of these family members or relatives passed away due to
cancer caused by HDGC? (Please list relatives).
The following questions will ask you to think about how your diagnosis of HDGC
has or has not impacted your education.
22. What was the highest degree or level of education you have completed?
a. Some high school
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b. Completed high school
c. Some college
d. Trade / Technical / Vocational training
e. Associate degree
f. Bachelor’s degree
g. Master’s degree
h. Doctorate degree
23. How do you feel about the following statements:
a. Having HDGC has…
Strongly
disagree

Somewhat
disagree

Neither
agree nor
disagree

Somewhat
agree

Strongly
agree

Had a negative impact on
my education
Had a positive impact on
my education
Limited my ability to
move away for school
Affected my class
attendance
Impacted my performance
in school
Impacted what I chose to
study
Impacted the timing in
which I pursued my
education

24. Please use the space below to elaborate on any of the above statements and/or tell us
more about how your diagnosis of HDGC has or has not impacted your education:
The following questions will ask you to think about how your diagnosis of HDGC
has or has not impacted your career choices and work life.
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25. Which option best describes your current employment status?
a. I am currently working in the field I would consider my career
b. I am currently working, but in a field I would consider temporary
c. I am not currently working due to reasons involving HDGC (e.g. recovering
from gastrectomy)
d. I am not currently working for other reasons (e.g. school, personal choice)
e. I have never been employed [skip to next section]
26. How do you feel about the following statements:
a. Having HDGC has…

Strongly
disagree

Somewhat
disagree

Neither
agree nor
disagree

Somewhat
agree

Strongly
agree

Had a negative impact on
my career
Had a positive impact on
my career
Influenced my choice of
career
Affected my performance
at my job
Limited my ability to
move away for a job
Caused me to have to take
time off work
Kept me from advancing
to a higher position

27. Please use the space below to elaborate on any of the above statements and/or tell us
more about how your diagnosis of HDGC has or has not impacted your career:
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The following questions will ask you to think about how your diagnosis of HDGC
has or has not impacted your relationships with romantic partners, family members,
and friends.
28. What is your current relationship status?
a. Single
b. In a committed relationship
c. Married
d. Domestic Partner
e. Separated
f. Divorced
g. Widow/Widower
29. How much would you say your diagnosis of HDGC has impacted the following
aspects of your romantic relationships?
None at
all

A little

Meeting prospective partners
Dating
Forming meaningful
connections
Emotional intimacy
Sexual intimacy
Maintaining relationships
Going out on dates and other
social activities
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A lot

A great
deal

	
  
	
  
	
  
	
  
30. Please use the space below to elaborate on any of the above statements and/or tell us
more about how your diagnosis of HDGC has or has not impacted your romantic
relationships:
31. Please rate the following statements in terms of how they apply to only your
relationships with family members.
Strongly
disagree

Somewhat Neither
disagree agree nor
disagree

Somewhat
agree

Strongly
agree

Living with HDGC has
helped me know who I can
count on in times of
trouble
I feel supported by my
family in regards to living
with HDGC
Living with HDGC has
helped me become more
aware of the love and
support available from my
family
Living with HDGC has
brought our family closer
together
HDGC has caused tension
/ strained relationships
within the family
I feel better equipped to
handle living with HDGC
because of my family

32. Please use the space below to elaborate on any of the above statements or tell us more
about how your diagnosis of HDGC has or has not impacted relationships with family
members.
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33. Please rate the following statements in terms of how they apply to only your
relationships with your friends.
Strongly Somewhat
disagree disagree

Neither
agree nor
disagree

Somewhat
agree

Strongly
agree

Living with HDGC has
helped me know who I
can count on in times of
trouble
Living with HDGC has
helped me become closer
to people I care about
Living with HDGC has
helped me become more
aware of the support
available from my friends
Living with HDGC has
caused me to miss out on
social activities
My friends understand
what HDGC is and how it
affects me
I feel supported by my
friends in regards to living
with HDGC

34. Please use the space below to elaborate on any of the above statements and/or tell us
more about how your diagnosis of HDGC has or has not impacted your relationships
with your friends.
The following questions will ask you to think about how your diagnosis of HDGC
has or has not impacted your decisions about having children.
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In vitro fertilization (IVF) with preimplantation genetic diagnosis (PGD): IVF with PGD
is an assisted reproductive technique that allows an embryo to be tested for a CDH1
mutation before it is implanted into the woman's uterus. Only embryos that do not have
the mutation are implanted.
35. Do you have children?
a. Yes
b. No
36. (If “yes” to Q35) Did you have your children before you were diagnosed with
HDGC?
a. Yes
b. No
37. (If “no” to Q36) Please check all that apply
a. I had my child(ren) without using assisted reproductive techniques (I
conceived naturally)
b. I had my child(ren) using in vitro fertilization (IVF)
c. I had my child(ren) using in vitro fertilization and pre-implantation genetic
diagnosis (IVF and PGD)
d. I had my child(ren) using a donor egg or donor sperm
e. My child(ren) is/are adopted
38. (If “yes” to Q35) Do you plan to have more children?
a. Yes
b. No
c. I haven’t thought about it yet
d. I am undecided
39. (If “no” to Q35) Do you plan to have children?
a. Yes
b. No
c. I haven’t thought about it yet
d. I am undecided
40. (If “yes” to: do you plan to have more children? Do you plan to have children?)
Which of the following have you considered for having future children, or are
undergoing already? Check all that apply
a. Having children without using assisted reproductive technologies (conceiving
naturally)
b. Adopting children
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c. Using in vitro fertilization
d. Using in vitro fertilization and pre-implantation genetic diagnosis
e. Using a donor egg or sperm
41. To what extent has your diagnosis of HDGC influenced your position on having or
not having children?
a. A great deal
b. A lot
c. A moderate amount
d. A little
e. None at all
42. Please use the space below to tell us more about how your diagnosis of HDGC has or
has not influenced your family planning:
The following questions will ask you to think about your experiences with a genetic
counselor (if any) and/or other healthcare providers.
43. Have you ever seen a genetic counselor regarding your diagnosis of HDGC?
a. Yes
b. No [skip to Q47]
44. [If “yes” to Q43] How would you rate your overall experience with your genetic
counselor?
a. I thought my genetic counseling session(s) was/were…
i. Not at all useful
ii. Slightly useful
iii. Moderately useful
iv. Very useful
v. Extremely useful
vi. I don't remember my genetic counseling session [skip to Q46]
45. To what extent do you agree/disagree with the following statements about your
genetic counseling session?
Strongly Somewhat
disagree disagree

Neither
agree
nor
disagree
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The genetic counselor
provided me with an
appropriate amount of
information
The genetic counselor
answered all the
questions I had in a
satisfactory manner
The genetic counselor
was sensitive and
attentive to my needs
and emotions
The genetic counselor
made me feel supported
and comfortable

46. Please use the space below to elaborate on any of the above statements or tell us
anything else about your experience(s) with your genetic counselor and/or other
healthcare providers.
47. Do you think having a CDH1 mutation has affected your overall quality of life?
Please use the space below to elaborate.
48. If there is anything else that you would like to share with us about living with HDGC
that we have not addressed in this survey, please use the space below:
49. Thank you for completing my survey! We are interviewing a subsection of
participants over the phone to gain further insight. If you would like to participate,
please provide your contact information below and we may contact you to schedule
an interview:
a. Name
b. Email address
c. Phone number
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APPENDIX C
TELEPHONE INTERVIEW GUIDE
Informed consent statement:
You are agreeing to participate in a telephone interview as a part of a genetic counseling
graduate school research project. This goal of this study is to gain perspective from
emerging adults ages 18- 29 about how having hereditary diffuse gastric cancer has
affected your life. The findings of this study may provide future benefit to others with
HDGC. Your participation in this project is voluntary and you may choose to end the
interview at any time. If at any time there is a question you are not comfortable
answering, please let me know and we can proceed on to the next question. The interview
will last approximately 30 minutes.
With your consent, this conversation will be recorded and transcribed. All responses
gathered from the interviews will be kept anonymous and confidential. If a quotation is
used from this interview, all identifying information will be removed and you will be
assigned an alternative name.
Before we begin, do you have any questions?
1. Can you tell me about the cancers in your family?
a. What happened? When?
2. What age were you when you first learned about HDGC?
a. How do you recall finding out about the chance for you to have HDGC?
3. What motivated you to have genetic testing?
4. Have you had or do you plan to have a prophylactic total gastrectomy?
a. Why or why not?
5. How has having a CDH1 mutation impacted your education?
6. How has having a CDH1 mutation impacted your employment?
7. How has having a CDH1 mutation impacted your social life?
8. How has having a CDH1 mutation impacted your friendships?
a. Do your friends have a good understanding of what HDGC is?
b. Do you feel supported by your friends in regards to HDGC?
9. How has having a CDH1 mutation impacted your family relationships?
a. How does your family communicate about HDGC? Is it an open topic?
10. How has having a CDH1 mutation impacted your romantic relationships?
11. How has having a CDH1 mutation impacted your plans for having children?
12. How did finding out about your CDH1 mutation affect your life plans?
13. Is there anything you wish you would have been told upon diagnosis?
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14. What do you want medical professionals who are working with HDGC patients to
know?
15. What would you like to say to future individuals in your position?
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